Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.

Journal Article (Journal Article)

BACKGROUND: Infant responses to vaccines can be impeded by maternal antibodies and immune system immaturity. It is therefore unclear whether human immunodeficiency virus type 1 (HIV-1) vaccination would elicit similar responses in adults and infants. METHOD: HIV-1 Env-specific antibody responses were evaluated in 2 completed pediatric vaccine trials. In the Pediatric AIDS Clinical Trials Group (PACTG) 230 protocol, infants were vaccinated with 4 doses of Chiron rgp120 with MF59 (n=48), VaxGen rgp120 with aluminum hydroxide (alum; n=49), or placebo (n=19) between 0 and 20 weeks of age. In PACTG 326, infants received 4 doses of ALVAC-HIV-1/AIDSVAX B/B with alum (n=9) or placebo (n=13) between 0 and 12 weeks of age. RESULTS: By 52 weeks of age, the majority of maternally acquired antibodies had waned and vaccine Env-specific immunoglobulin G (IgG) responses in vaccinees were higher than in placebo recipients. Chiron vaccine recipients had higher and more-durable IgG responses than VaxGen vaccine recipients or ALVAC/AIDSVAX vaccinees, with vaccine-elicited IgG responses still detectable in 56% of recipients at 2 years of age. Remarkably, at peak immunogenicity, the concentration of anti-V1V2 IgG, a response associated with a reduced risk of HIV-1 acquisition in the RV144 adult vaccine trial, was 22-fold higher in Chiron vaccine recipients, compared with RV144 vaccinees. CONCLUSION: As exemplified by the Chiron vaccine regimen, vaccination of infants against HIV-1 can induce robust, durable Env-specific IgG responses, including anti-V1V2 IgG.

Full Text

Duke Authors

Cited Authors

  • Fouda, GG; Cunningham, CK; McFarland, EJ; Borkowsky, W; Muresan, P; Pollara, J; Song, LY; Liebl, BE; Whitaker, K; Shen, X; Vandergrift, NA; Overman, RG; Yates, NL; Moody, MA; Fry, C; Kim, JH; Michael, NL; Robb, M; Pitisuttithum, P; Kaewkungwal, J; Nitayaphan, S; Rerks-Ngarm, S; Liao, H-X; Haynes, BF; Montefiori, DC; Ferrari, G; Tomaras, GD; Permar, SR

Published Date

  • February 15, 2015

Published In

Volume / Issue

  • 211 / 4

Start / End Page

  • 508 - 517

PubMed ID

  • 25170104

Pubmed Central ID

  • PMC4318918

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiu444


  • eng

Conference Location

  • United States